By John Carroll When George Scangos (photo) was named to the top post at Biogen Idec, there were a considerable number of discussions in the industry that started with a simple question. George who? But over the past 10 months, the former Exelixis CEO has restructured the pipeline, put in his own team of top …
By John Carroll Biogen Idec’s new CEO, George Scangos (photo), is prepared to bring out the company’s check book to build up its franchise of new drugs for noncancerous diseases of the blood. The big biotech, which has two new drugs for hemophilia in late-stage development, is looking to add to the portfolio by in-licensing or …
By John Carroll After three years of partnering with Switzerland’s Neurimmune Therapeutics on antibody discovery programs targeting the CNS field, Biogen Idec ($BIIB) has opted to seal their deal with a pact to acquire one of its subsidiaries outright for up to $427.5 million. The package kicks off with a $32.5 million upfront and follows with …
By John Carroll Biogen Idec is buddying up to Knopp Neurosciences with $80 million in cash and up to $245 million more in various milestones for marketing rights to a promising, late-stage ALS drug. Biogen will invest $60 million in the Pittsburgh, PA-based developer while providing another $20 million as an upfront for the company. …
